Marketed by: Teva Pharmaceuticals
Compare to: Folex (discontinued) (Pharmacia Corporation, now part of Pfizer Inc)
Indication: Teva Pharmaceuticals announces the introduction of its generic methotrexate injection for the treatment of certain cancers, including acute lymphoblastic leukemia, severe psoriasis that has not responded to other forms of therapy, and adult rheumatoid arthritis. It is non-pyrogenic and may be administered by intramuscular, intravenous, or intra-arterial routes. The injection is free of both latex and plastic. The injection can cause fetal death or birth defects when administered to pregnant women, and pregnancy should be avoided if either partner is on the medication.
Dosage Form: 25 mg/mL single-dose glass vials and in 50 mg, 100 mg, 250 mg, and 1 g doses
For More Information: www.tevausa.com
Oxycodone HCl Capsules
Marketed by: Midlothian Laboratories (Montgomery, AL)
Compare to: Oxycodone HCl 5 mg (Lehigh Valley Technologies Inc.)
Indication: Midlothian Laboratories has begun distributing oxycodone in capsule form, an AB-rated generic equivalent of Lehigh Valley Technologies' Oxycodone HCl 5 mg. It is indicated for the management of moderate to severe acute and chronic pain and is available in a single strength. Each gelatin capsule contains 5 mg of the drug, and should be taken every 4 to 6 hours as needed.
Dosage Form: Capsules: 5 mg
For More Information: www.midlothianlabs.com
Marketed by: Sandoz Inc (Princeton, NJ)
Compare to: Dovonex (LEO Pharma Inc)
Indication: Sandoz has introduced calcipotriene cream, the first generic version of LEO Pharma Inc’s Dovonex Cream. The cream is indicated for the treatment of plaque psoriasis and contains a synthetic vitamin D3 derivative that is absorbed systemically. It is applied to psoriasis plaques on the body twice daily but should not be used on the face.
Dosage Form: Topical cream: 0.005% in 60- and 120-g tubes
For More Information: www.us.sandoz.com
Levalbuterol HCl Inhalation Solution
Marketed by: Prasco Laboratories (Mason, OH)
Compare to: Xopenex (Sunovion Pharmaceuticals Inc)
Indication: Prasco Laboratories and Sunovion Pharmaceuticals Inc will begin distributing levalbuterol HCL, an authorized generic version of Sunovion’s Xopenex inhalation solution. It is indicated for the prevention or relief of bronchospasm caused by asthma and chronic obstructive pulmonary disease. The medication can be used by adults, adolescents, and children 4 years and older.
Dosage Form: Metered-dose inhaler: 1.25 mg/ 3 mL, 0.63 mg/3 mL, and 0.31 mg/3 mL strengths
For More Information: www.prasco.com